دورية أكاديمية
Impact of a Clinical Pharmacist Intervention Program on the Follow-up of Type-2 Diabetic Patients.
| العنوان: | Impact of a Clinical Pharmacist Intervention Program on the Follow-up of Type-2 Diabetic Patients. |
|---|---|
| المؤلفون: | Ebid AI; Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University, Cairo, Egypt., Mobarez MA; Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University, Cairo, Egypt., Ramadan RA; Ahmed Maher Teaching Hospital, portsaid, Cairo, Egypt., Mahmoud MA; Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University, Cairo, Egypt. |
| المصدر: | Hospital pharmacy [Hosp Pharm] 2022 Feb; Vol. 57 (1), pp. 76-82. Date of Electronic Publication: 2020 Nov 25. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sage Publications Country of Publication: United States NLM ID: 0043175 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0018-5787 (Print) Linking ISSN: 00185787 NLM ISO Abbreviation: Hosp Pharm Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: <2017-> : Thousand Oaks, CA : Sage Publications Original Publication: [Philadelphia] : Lippincott |
| مستخلص: | Aims: The primary aim of this current study was to investigate the impact of the clinical pharmacist interventions on glycemic control and other health-related clinical outcomes in patients with type 2 diabetes in Egypt. Methods: A prospective trial was conducted on 100 patients with uncontrolled type 2 diabetes admitted in the diabetes outpatient's clinics. Patients were randomly allocated into the clinical pharmacist intervention group and usual care group. In the intervention group, the clinical pharmacist, in collaboration with the physician had their patients receive pharmaceutical care interventions. In contrast, the usual care group patients received routine care without clinical pharmacist's interference. Results: After 6-month of follow-up, of the average HbA1c and FBG values of the patients in the clinical pharmacist intervention group (HbA1c % from 8.6 to 7.0; FBG (mg/dL) from 167.5 to 121.5) decreased significantly compared to the usual care group patients (HbA1c % from 8.1 to 7.8; FBG (mg/dL) from 157.3 to 155.9) ( P < .05). Additionally, the results indicated that mean scores of patients 'diabetes knowledge, medication adherence, and diabetes self-care activities of the patients in the clinical pharmacist group increased significantly compared to the control group ( P < .05). Conclusions: The study demonstrated an improvement in HbA1c, FBG, and lipid profile, in addition to self-reported medication adherence, diabetes knowledge, and diabetes self-care activities in patients with type 2 diabetes who received pharmaceutical care interventions. The study outcomes support the benefits and the need to integrate clinical pharmacist interventions in the multidisciplinary healthcare team in Egypt. Competing Interests: Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© The Author(s) 2020.) |
| References: | Diabet Med. 2007 Jun;24(6):677-83. (PMID: 17523968) Value Health. 2000 Nov-Dec;3 Suppl 1:3-6. (PMID: 16464204) Diabetes Care. 2006 Apr;29(4):823-9. (PMID: 16567822) Br J Clin Pharmacol. 2009 May;67(5):547-57. (PMID: 19552750) J Gen Intern Med. 2007 Apr;22(4):442-7. (PMID: 17372790) Am J Health Syst Pharm. 2006 Nov 1;63(21):2116-22. (PMID: 17057049) Diabetes Care. 2004 Dec;27(12):2983-4. (PMID: 15562220) Ann Glob Health. 2015 Nov-Dec;81(6):814-20. (PMID: 27108148) Pharm World Sci. 2006 Apr;28(2):65-72. (PMID: 16791717) Med Care. 1986 Jan;24(1):67-74. (PMID: 3945130) J Diabetes Complications. 2012 Jan-Feb;26(1):10-6. (PMID: 22226484) Diabetes Res Clin Pract. 2018 Oct;144:63-73. (PMID: 30056190) Eval Health Prof. 1996 Jun;19(2):208-30. (PMID: 10186911) J Manag Care Spec Pharm. 2016 May;22(5):493-515. (PMID: 27123912) Diabetes Care. 2000 Jul;23(7):943-50. (PMID: 10895844) Am J Manag Care. 2005 Apr;11(4):253-60. (PMID: 15839185) Am J Med. 2005 Mar;118(3):276-84. (PMID: 15745726) Am J Manag Care. 2010 Apr;16(4):250-5. (PMID: 20394460) Patient Educ Couns. 2016 Jun;99(6):926-43. (PMID: 26658704) J Drug Assess. 2019 Jun 05;8(1):115-121. (PMID: 31231590) J Clin Pharm Ther. 2011 Oct;36(5):602-13. (PMID: 21143256) Front Neurosci. 2019 May 14;13:458. (PMID: 31139045) Am J Health Syst Pharm. 2016 Jan 1;73(1):e63-6. (PMID: 26683684) J Clin Pharm Ther. 2006 Oct;31(5):409-19. (PMID: 16958818) Am J Health Syst Pharm. 2006 Jul 15;63(14):1325-31. (PMID: 16809752) Diabetes Obes Metab. 2018 Jan;20(1):185-194. (PMID: 28730750) Diabetes Care. 2008 Jan;31 Suppl 1:S97-104. (PMID: 18165344) J Am Pharm Assoc (2003). 2008 Nov-Dec;48(6):722-30. (PMID: 19019800) Pharmacotherapy. 2006 Feb;26(2):248-53. (PMID: 16466329) Endocr Pract. 2011 Mar-Apr;17(2):287-302. (PMID: 21474421) Ann Pharmacother. 2005 Mar;39(3):433-40. (PMID: 15701763) Am J Ther. 2014 Jul-Aug;21(4):234-9. (PMID: 23344108) J Res Med Sci. 2011 Jan;16(1):43-9. (PMID: 21448382) Diabetes Care. 2020 Aug;43(8):1981. (PMID: 32503833) J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):57-64. (PMID: 21335480) BMJ. 2008 Mar 1;336(7642):491-5. (PMID: 18276664) Diabetes Care. 2005 Apr;28(4):771-6. (PMID: 15793171) |
| فهرسة مساهمة: | Keywords: HbA1c; diabetes mellitus; education; pharmacists |
| تواريخ الأحداث: | Date Created: 20220506 Latest Revision: 20240827 |
| رمز التحديث: | 20240827 |
| مُعرف محوري في PubMed: | PMC9065514 |
| DOI: | 10.1177/0018578720973881 |
| PMID: | 35521013 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0018-5787 |
|---|---|
| DOI: | 10.1177/0018578720973881 |